Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Moderna, Inc.

< Previous 1 2 3 4 5 Next >
Moderna to Present at Upcoming Investor Conferences in November 2021
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Named a Top Employer by Science for Seventh Consecutive Year
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces First Participant Dosed in Phase 3 Pivotal Registration Study of Its mRNA Cytomegalovirus (CMV) Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Swissmedic Authorizes Booster Dose of Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Memorandum of Understanding to Supply up to 110 Million Doses of Its COVID-19 Vaccine to the African Union
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces European Medicines Agency’s Committee for Medicinal Products for Human Use Recommends Booster Dose of Moderna’s COVID-19 Vaccine in the European Union
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Positive Top Line Data from Phase 2/3 Study of COVID-19 Vaccine in Children 6 to 11 Years of Age
From Moderna, Inc.
Via Business Wire
Tickers MRNA
U.S. CDC Advisory Committee on Immunization Practices Recommends Booster Vaccination with Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces FDA Authorization of a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces FDA Advisory Committee Unanimously Votes in Support of Emergency Use for a Booster Dose of Moderna’s COVID-19 Vaccine in the U.S.
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Report Third Quarter Financial Results on Thursday, November 4, 2021
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces COVAX Exercises Option to Purchase 176.5 Million Additional Doses of Moderna’s COVID-19 Vaccine for Low Income Countries in First Half of 2022
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Build State-of-the-Art mRNA Facility in Africa to Manufacture up to 500 Million Doses Per Year
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces the Launch of Global Fellowship Program for Young Researchers Exploring mRNA Medicines
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces European Medicines Agency Authorizes Third Dose of COVID-19 Vaccine for Immunocompromised Individuals Aged 12 Years and Older
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Invest in New Science Center in Cambridge, MA
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Present at Chardan’s Virtual 5th Annual Genetic Medicines Conference
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Supply Agreement with Peru for 20 Million Doses of Its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Health Canada Approves its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Highlights New Clinical Data on its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Significant Advances Across Industry-Leading mRNA Portfolio at 2021 R&D Day
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Resilience to Manufacture mRNA for Moderna’s COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna and the Institute for Life Changing Medicines Announce a New Collaboration to Develop an mRNA Therapeutic for Ultra-Rare Disease, Crigler-Najjar Syndrome Type 1
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Present at Upcoming Investor Conferences in September 2021
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna to Host Virtual R&D Day on Thursday, September 9, 2021
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces Supply Agreement with Canada for Expanded Supply of Moderna’s COVID-19 Vaccine in 2022, in 2023 and in 2024
From Moderna, Inc.
Via Business Wire
Tickers MRNA
Moderna Announces First Patient Dosed in Phase 1/2 Study of mRNA-3705 for Methylmalonic Acidemia
From Moderna, Inc.
Via Business Wire
Tickers MRNA
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.